(PPH) Pharmaceutical - Overview
Exchange: NASDAQ •
Country: USA •
Currency: USD •
Type: Etf •
ISIN: US92189F6925
Etf: Pharmaceuticals, Medicines, Drugs, Healthcare
Total Rating 53
Risk 67
Buy Signal -0.68
| Risk 5d forecast | |
|---|---|
| Volatility | 16.1% |
| Relative Tail Risk | -1.07% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.66 |
| Alpha | 6.50 |
| Character TTM | |
|---|---|
| Beta | 0.365 |
| Beta Downside | 0.349 |
| Drawdowns 3y | |
|---|---|
| Max DD | 18.06% |
| CAGR/Max DD | 0.81 |
Description: PPH Pharmaceutical March 05, 2026
PPH is an ETF that invests at least 80% of its assets in pharmaceutical companies. These include U.S. exchange-listed common stocks and depositary receipts, encompassing medium-capitalization and foreign companies.
The pharmaceutical industry is characterized by significant research and development investments and lengthy drug approval processes. Its business model relies on patent protection for new drugs to ensure profitability.
For more detailed analysis of PPH and its holdings, consider exploring ValueRay.
Headlines to watch out for
- Drug pipeline success boosts pharmaceutical company valuations
- Patent expirations reduce revenue for major drug manufacturers
- Healthcare policy changes impact pharmaceutical pricing and demand
- Research and development costs influence drug profitability
- Global health crises increase demand for pharmaceutical products
What is the price of PPH shares?
As of March 16, 2026, the stock is trading at USD 104.36 with a total of 1,105,457 shares traded.
Over the past week, the price has changed by -2.59%, over one month by -6.53%, over three months by +1.98% and over the past year by +14.13%.
Over the past week, the price has changed by -2.59%, over one month by -6.53%, over three months by +1.98% and over the past year by +14.13%.
Is PPH a buy, sell or hold?
Pharmaceutical has no consensus analysts rating.
What are the forecasts/targets for the PPH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |